Efficacy of Oral Selinexor plus Low Dose Dexamethasone (Sd) in Patients with Penta-Refractory Myeloma: Results of the Pivotal STORM Part II Study

S. Jagannath, DT. Vogl, MA. Dimopoulos, A. Nooka, C. Huff, P. Moreau, C. Cole, J. Richter, D. Dingli, R. Vij, S. Tuchman, M. Raab, K. Weisel, M. Delforge, D. Kaminetzky, RF. Cornell, AK. Stewart, J. Hoffman, KN. Godby, TL. Parker, M. Levy, M. Schreder, N. Meuleman, L. Frenzel, M. Mohty, S. Choquet, A. Yee, M. Gavriatopoulou, LJ. Costa, J. Shah, C. Picklesimer, JR. Saint-Martin, L. Li, MG. Kauffman, S. Shacham, P. Richardson, A. Chari

Disclosures

Research Support:	Karyopharm, Janssen, Celgene, Amgen, GSK		
Consultant	n/a		
Honoraria	Karyopharm, Janssen, Celgene, GSK		
Scientific Advisory Board	Janssen, Celgene, Amgen, GSK		
Major Stockholder	n/a		
Employee, Speakers Bureau	n/a		

Acknowledgments

Patients, their families, and caregivers

Investigators, co-investigators and study teams at each participating center


- Icahn School of Medicine at Mount Sinai, New York, NY
- Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA
- National and Kapodistrian University of Athens, Athens, Greece
- Winship Cancer Center at Emory University, Atlanta, GA
- Kimmel Cancer Center at John Hopkins, Baltimore, MD
- Nantes University Hospital Center, Nantes, France
- University of Michigan, Ann Arbor, MI
- Dana Farber Cancer Institute, Boston, MA
- John Therurer Cancer Center at Hackensack University, Hackensack, NJ
- Mayo Clinic Rochester, Rochester, NY
- Siteman Cancer Center at Washington University, St. Louis, MO
- University of North Carolina, Chapel Hill, NC
- Heidelberg University Hospital, Heidelberg, Germany

- University Hospital of Tübingen, Tübingen, Germany
- University Hospital Leuven, Leuven, Belgium
- Perlmutter Cancer Center at NYU, New York, NY
- Ingram Cancer Center at Vanderbilt University, Nashville, TN
- Mayo Clinic Arizona, Scottsdale, AZ
- Sylvester Comprehensive Cancer Center at University of Miami
- University of Alabama, Birmingham, AL
- Yale University, New Haven, CT
- Baylor University, Dallas, TX
- University Hospital Wuerzburg, Wuerzburg, Germany
- Institut Jules Bordet, Brussels, Belgium
- Necker Children's Hospital, Paris, France
- Hopital Saint Antoine, Paris, France
- La Pitie-Salpetriere University Hospital, Paris, France
- Massachusetts General Hospital, Boston, MA

This study was sponsored by Karyopharm Therapeutics

Background: Penta-Refractory Myeloma


- Multiple myeloma (MM) remains largely incurable despite novel therapies; ~13,000 deaths anticipated in USA in 2018¹
- With increased use of novel agents, a growing number of patients are exposed to bortezomib(B), carfilzomib(C), lenalidomide(L), pomalidomide(P) and daratumumab(D) and developing MM refractory to PIs, IMiDs, and daratumumab
- There are no approved drugs with established clinical activity in penta-refractory MM
- Patients with penta-refractory MM have poor overall survival, estimated at 3.5 months², representing a high unmet medical need



¹ Cancer Facts and Figures, ACS. 2018 ² Pick et al. Eur J Haematol. 2018;100:494

Selinexor:

First in Class, Oral Selective Inhibitor of Nuclear Export (SINE)¹⁻³



¹Schmidt et al., Leukemia, 2013, ²Tai et al., Leukemia, 2013, ³Argueta et al., Oncotarget, 2018

Exportin 1 (XPO1) is the major nuclear export protein for:

- Tumor suppressor proteins (TSPs, e.g p53, IκB and FOXO)
- Glucocorticoid receptor (GR)
- eIF4E-bound oncoprotein mRNAs (e.g., c-Myc, BCL-xL, cyclins)

XPO1 is overexpressed in MM:

- High XPO1 levels enable cancer cells to escape TSP mediated cell cycle arrest and induction of apoptosis
- XPO1 levels correlate with poor prognosis and drug resistance

Selinexor is an oral selective **XPO1** inhibitor; preclinical data supports that selinexor :

- Reactivates multiple TSPs relevant to MM, inhibits NF-κB signaling and reduces c-Myc levels
- In combination with dexamethasone (dex) reactivates GR signaling

Selinexor + Dexamethasone: Initial Clinical Data in RRMM

Phase 1 Clinical Trial of Selinexor (Chen et al, Blood 2017) (N=81 patients):

- Enrolled patients with heavily pretreated MM
- R2PD was Selinexor 45 mg/m² (~80 mg) and dex (20 mg) given twice weekly
- The combination demonstrated an ORR of 50% (n=12 patients)

Phase 2b STORM Clinical Trial Part 1 (Vogl et al, JCO 2018) (N=79 patients)

- Enrolled both quad- (B,C,L,P) or penta-refractory (B,C,L,P, anti-CD38) MM
- Selinexor/dexamethasone was administered either 3/4 or 4/4 weeks
- Main side effects: nausea, anorexia, fatigue, thrombocytopenia, hyponatremia, and anemia
- Overall response rate (ORR) of 21%

Pivotal STORM Part II: Study Design



Selinexor / dexamethasone twice weekly (Days 1 and 3) until Disease Progression

Patient Population:

- MM previously treated with bortezomib, carfilzomib, lenalidomide, pomalidomide, daratumumab, an alkylator, and glucocorticoids.
- Disease <u>documented</u> to be refractory to ≥1 PI, ≥1 IMiD, daratumumab, glucocorticoid and last line of therapy

Primary Endpoint:

Overall Response rate: ORR

Secondary Endpoints: Duration of Response (DOR), Clinical benefit rate (CBR), Overall survival (OS), Progression free survival (PFS) Safety

Key Inclusion/Exclusion:

- Creatinine clearance ≥
 20 mL/min
- ANC \geq 1,000/mm³,
- Platelets ≥ 75,000/mm³ (if bone marrow plasma cell > 50%; plt > 50,000/mm³
- Hemoglobin \geq 8.5 g/dL

Pivotal STORM Part II: Patient Characteristics

	N=122*		
Age, years median (range)	65 (40 – 86)		
Time from Diagnosis, Years median (range)	6.6 (1.1 – 23.4)		
Males : Females	71 M (58%) : 51 F (42%)		
Creatinine Clearance < 60 mL/min	40 (32%)		
High Risk Cytogenetics: (del17p, t(4;14), t(14;16), 1q21)	65 (53%)		
MM Subtype: FLC	35 (29%)		
ECOG Performance Status: 0 / 1 / 2 / Unk	30% / 58% / 9% / 2%		
Revised International Staging System (R-ISS): I / II / III / Unk	16% / 64% / 19% / <1%		

*A total of 123 patients were enrolled, however 1 patient did not meet eligibility criteria, thus was excluded from this analysis

Pivotal STORM Part II: Prior Therapies

	N=122
Median Prior Regimens (range)	7 (3 – 18)
Number of Prior Treatment Regimens ≤6 7-8 ≥9	48 (39%) 38 (31%) 36 (30%)
Prior Treatments -Refractory to PI / IMiD / Daratumumab / Glucocorticoid -Refractory to Carfilzomib/Pomalidomide/Daratumumab -Refractory to 2 PIs / 2 IMiDs / Daratumumab	122 (100%) 117 (96%) 83 (68%)
-Stem Cell Transplant - ≥2 Transplants -Intensive Combination Chemotherapy (e.g. DT-PACE) -Daratumumab in Last Prior Regimen -Daratumumab in Combination -CAR-T Cell Therapy	102 (84%) 29 (28%) 32 (26%) 58 (48%) 86 (70%) 2 (2%)

Pivotal STORM Part II:

Treatment Related Non-Hematological Adverse Events in ≥10% of Patients

Gastrointestinal Disorders	Grade 1	Grade 2	Grade 3	Grade 4	Total (N=122)
Nausea	32 (26.0%)	41 (33.3%)	12 (9.8%)		85 (69.1%)
Anorexia	19 (15.4%)	41 (33.3%)	4 (3.3%)		64 (52.0%)
Vomiting	18 (14.6%)	21 (17.1%)	4 (3.3%)		43 (35.0%)
Diarrhea	21 (17.1%)	12 (9.8%)	8 (6.5%)		41 (33.3%)
Altered Taste	7 (5.7%)	5 (4.1%)			12 (9.8%)
Constipation	8 (6.5%)	3 (2.4%)	1 (0.8%)		12 (9.8%)
Constitutional					
Fatigue/Asthenia	16 (13.0%)	42 (34.1%)	28 (22.8%)		86 (69.9%)
Weight Loss	31 (25.2%)	26 (21.1%)	1 (0.8%)		58 (47.2%)
Dizziness	10 (8.1%)	3 (2.4%)			13 (10.6%)
Other					
Hyponatremia	18 (14.6%)		20 (16.3%)		38 (30.9%)
Insomnia	8 (6.5%)	3 (2.4%)	2 (1.6%)		13 (10.6%)
Pneumonia ¹		2 (1.6%)	3 (2.4%)		6 (4.9%)
Sepsis ²				1 (0.8%)	2 (1.6%)

¹Pneumonia – 1 Grade 5 Event

²Sepsis – 1 Grade 5 Event

10

Pivotal STORM Part II:


Treatment Related Hematological Adverse Events in ≥10% of Patients

Adverse Event Term	Grade 1	Grade 2	Grade 3	Grade 4	Total (N=122)
Thrombocytopenia	10 (8.1%)	7 (5.7%)	28 (22.8%)	38 (30.9%)	83 (67.5%)
Anemia	5 (4.1%)	18 (14.6%)	35 (28.5%)	1 (0.8%)	59 (48.0%)
Neutropenia*	6 (4.9%)	16 (13.0%)	18 (14.6%)	4 (3.3%)	44 (35.8%)
Leukopenia	6 (4.9%)	13 (10.6%)	17 (13.8%)		36 (29.3%)
Lymphopenia	2 (1.6%)	4 (3.3%)	8 (6.5%)	3 (2.4%)	17 (13.8%)

*Febrile Neutropenia (Grade 3) in 2 patients (1.6%)

23 patients (19.5%) discontinued due to treatment related AE


Pivotal STORM Part II: Efficacy




- In penta-refractory MM patients with a median of 7 prior treatment regimens, **ORR of 26.2%,** including **2 stringent CRs**
 - sCRs were MRD negative at 10⁻⁶ and 10⁻⁴
- Median time to response was 1
 month (range 1 to 14 weeks)
- 16 patients (13.1%) progressed (PD) on therapy and 10 patients (8.2%) were not evaluable for response

Responses as of August 17, 2018 were adjudicated according to the IMWG criteria *(Kumar, 2016)* by an independent review committee (IRC).

Pivotal STORM Part II: Efficacy Sub-Groups




Pivotal STORM Part II: Duration of Response (patients ≥PR)



Duration of Response


- The median duration of response is 4.4 months ranging (<1 – 12.2 months)
- Responses typically occurred within the first cycle (4 weeks) of treatment with Sd

Pivotal STORM Part II: Progression Free Survival



Category	All Patients (N=122)	≥ PR (N=32)	≥ MR (N=48)	SD (N=48)	PD/NE (N=26)
Median PFS	3.7 Months	5.3 Months	4.6 Months	2.2 Months	1.1 Months

Pivotal STORM Part II: Overall Survival



Category	All Patients (N=122)	≥ PR (N=32)	≥ MR (N=48)	SD (N=48)	PD/NE (N=26)
Median OS	8.6 Months	15.6 Months	15.6 Months	6.3 Months	1.7 Months

Pivotal STORM Part II: Conclusions

- Selinexor plus dexamethasone is an all-oral, first in class investigational treatment with a novel mechanism of action
- Most important G3/4 AEs: thrombocytopenia (53.7%); anemia (29.3%); fatigue (22.8%); hyponatremia (16.3%); nausea (9.8%); diarrhea (6.5%); anorexia (3.3%), emesis (3.3%)
- Selinexor plus dexamethasone achieved:
 - ORR of <u>26.2%</u> in Penta–Refractory Myeloma
 - Duration of Response 4.4 months
 - Clinical Benefit Rate of **39.3%**; Disease Control Rate (≥SD) of **78.7%**
 - 2 patients achieved sCRs: both **MRD negative**
 - Each of the 2 patients with relapse after CAR-T therapy achieved a PR
- Median OS: 8.6 months; 15.6 months in pts that achieved ≥MR; 1.7 months in pts with PD/NE